Status:

RECRUITING

Nitrous Oxide and EMOtional Cognition

Lead Sponsor:

University of Oxford

Conditions:

Depression

Eligibility:

All Genders

18-40 years

Phase:

NA

Brief Summary

The goal of this study is to uncover the underlying neuropsychological mechanisms of nitrous oxide, which may be relevant to its reported antidepressant effects. In particular, the study is designed t...

Detailed Description

Questions regarding the mechanisms of nitrous oxide and its effects on the brain and behaviour in the context of its reported antidepressant effects remain largely unanswered. Thus, in the present stu...

Eligibility Criteria

Inclusion

  • Aged 18-40 years
  • Good vision and hearing
  • Willing and able to give informed consent
  • Body mass index (BMI) within the range of 18-35kg/m2 (This is to ensure we exclude underweight individuals who might have more substantial reactions to the nitrous oxide).
  • Sufficiently fluent in English to understand tasks
  • Willing to avoid drinking any alcohol from 3 days prior to Visit One until the end of Visit Three
  • Willing to avoid using recreational drugs for 3 months prior to Visit One and throughout the duration of the study

Exclusion

  • Receiving or seeking treatment for any mental health condition (covered in Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-5 (SCID) assessment in screening procedures)
  • History of any mental health condition (covered in SCID assessment in screening procedures)
  • Attention deficit hyperactivity disorder (ADHD) requiring treatment with stimulant or other centrally-acting drugs
  • A positive drug test for any of the following: amphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine, marijuana, methadone, methamphetamine, methylenedioxymethamphetamine (MDMA), morphine, methaqualone, opiates, phencyclidine, propoxyphene, tricyclic antidepressants, tramadol, ketamine, oxycodone, cotinine, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), fentanyl, synthetic marijuana, 6-mono-acetyl-morphine (6-MAM).
  • Regularly drink 14 or more units of alcohol a week
  • Any eye, throat or ear surgery or a medical procedure requiring intravenous injection or line into a vein in the last 6 months
  • A head injury causing concussion or unconsciousness in the past 6 months
  • A collapsed lung or lung surgery (e.g., pneumothorax)
  • A history of cardiac arrhythmias
  • Current injuries of the face or mouth (including ulcers or dental problems)
  • Dental surgery in the past month
  • Deep diving or scuba diving (which has a risk of decompression sickness) in past month
  • Pregnancy / intention to become pregnant during the study
  • Breastfeeding during the study
  • Asthma, emphysema or any medical condition that affects the lungs or breathing
  • Diagnosed vitamin B12 deficiency
  • Any use of recreational drugs in the last three months
  • Participation in any other drug study in the last three months
  • Participation in any other study with the same tasks in the last year
  • OPTIONAL SLEEP STUDY ADD-ON

Key Trial Info

Start Date :

July 10 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2025

Estimated Enrollment :

88 Patients enrolled

Trial Details

Trial ID

NCT06557642

Start Date

July 10 2024

End Date

October 1 2025

Last Update

July 31 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Psychiatry Department

Oxford, United Kingdom, OX3 7JX